Invivo therapeutics announces participation at upcoming h.c. wainwright bioconnect conference

Cambridge, mass.--(business wire)--invivo therapeutics holdings corp. (nasdaq: nviv), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that richard toselli, m.d., president and chief executive officer, will present at the upcoming virtual h.c. wainwright bioconnect conference, which runs from january 10 – 13, 2022. dr. toselli's presentation will provide an overview of the company and will also highlight
NVIV Ratings Summary
NVIV Quant Ranking